Compound class:
Peptide or derivative
|
References |
1. el-Shami K, Smith BD. (2008)
Immunotherapy for myeloid leukemias: current status and future directions. Leukemia, 22 (9): 1658-64. [PMID:18563174] |
2. Molldrem J, Dermime S, Parker K, Jiang YZ, Mavroudis D, Hensel N, Fukushima P, Barrett AJ. (1996)
Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood, 88 (7): 2450-7. [PMID:8839835] |
3. Molldrem JJ, Clave E, Jiang YZ, Mavroudis D, Raptis A, Hensel N, Agarwala V, Barrett AJ. (1997)
Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood, 90 (7): 2529-34. [PMID:9326217] |
4. Molldrem JJ, Lee PP, Wang C, Champlin RE, Davis MM. (1999)
A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res, 59 (11): 2675-81. [PMID:10363991] |